

Filed: August 29, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
Petitioner,

v.

BIOGEN MA, INC.
Patent Owner.

Patent No. 8,399,514

Inter Partes Review IPR2018-01403

**PETITIONER'S AMENDED NOTICE OF DEPOSITION OF
GILMORE O'NEILL, M.D.**

Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc., hereby provides notice that it will cross-examine Dr. Gilmore O'Neill, a witness of Patent Owner Biogen MA, Inc. The cross-examination will begin at 9:00 a.m. on September 13, 2019 at the law offices of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Two Seaport Lane, Boston, MA 02210-2001. The parties have agreed on this date for the cross-examination of Dr. O'Neill.

The cross-examination will be recorded by stenographic means by a court reporter licensed to administer oaths, and will also be recorded using audio and/or visual means.

Respectfully submitted,

PERKINS COIE LLP

Dated: August 29, 2019

By: /s/ Emily J. Greb

Emily J. Greb
Reg. No. 68,244
Perkins Coie LLP
33 East Main Street, Suite 201
Madison, WI 53703
Telephone: (608) 663-7494
E-mail: EGreb@perkinscoie.com

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing PETITIONER'S AMENDED NOTICE OF DEPOSITION OF GILMORE O'NEILL, M.D. was served electronically via e-mail as follows:

Patent Owner:

Barbara C. McCurdy
Mark J. Feldstein
Erin M. Sommers
Pier D. DeRoo
Cora R. Holt
Finnegan, Henderson, Farabow, Garrett
& Dunner, LLP
901 New York Avenue, NW
Washington, DC 20001
(202) 408-4047
barbara.mccurdy@finnegan.com
mark.feldstein@finnegan.com
erin.sommers@finnegan.com
pier.deroo@finnegan.com
cora.holt@finnegan.com

Dated: August 29, 2019

/s/Emily J. Greb
Emily J. Greb
Reg. No. 68,244

Counsel for Petitioner Mylan Pharmaceuticals Inc.